Editas Medicine (Nasdaq: EDIT) Q2 loss and cash runway into 2028
Rhea-AI Filing Summary
Editas Medicine, Inc. reported second quarter 2026 results, with collaboration and other research and development revenue of $11.9 million and a net loss of $18.2 million, or $0.15 per share, compared with a $53.2 million loss a year earlier. Cash and cash equivalents were $211.6 million as of June 30, 2026, and the company expects its cash runway to extend into the second half of 2028.
The company highlighted EDIT-401, its in vivo CRISPR program for Heterozygous Familial Hypercholesterolemia, stating it is on track to submit a Clinical Trial Notification in Australia this month and to initiate a Phase 1/2 trial, with a data update expected in the first quarter of 2027 and topline results in 2027. Preclinical non-human primate data showed roughly 90% or greater mean reductions in LDL-C, Lp(a), and ApoB after a single dose, with no adverse clinical observations at 1.5 mg/kg.
In May, Editas completed a public offering of common stock and warrants for aggregate gross proceeds of $125.0 million, with approximately $194.4 million in additional gross proceeds possible upon full warrant exercise. The company also announced that director Elliott Levy resigned and that Patrick Ellinor, M.D., Ph.D. was appointed as an independent class I director, with standard cash and equity compensation.
Positive
- Net loss for Q2 2026 decreased to $18.2 million (‑$0.15 per share) on $11.9 million revenue, while cash and cash equivalents rose to $211.6 million, supporting a stated cash runway into the second half of 2028.
Negative
- None.
Filing Explained
The board seat changes on August 6, with $40,000 annual cash pay and a 103,400-share option award; no share issuance is reported.
Editas Medicine reports that class I director Elliott Levy resigned effective
Under the director compensation policy, Ellinor will receive
The specific open item is the option's future vesting and exercise under those stated terms; this filing reports no exercise event.
8-K Event Classification
3 items: 2.02, 5.02, 9.01
3 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q2 2026 revenue: $11.9 million
Q2 2026 net loss: $18.2 million
Net loss per share Q2 2026: $0.15 per share
+5 more
8 metrics
Q2 2026 revenue
$11.9 million
Collaboration and other R&D revenues for the three months ended June 30, 2026
Q2 2026 net loss
$18.2 million
Net loss attributable to common stockholders for the three months ended June 30, 2026
Net loss per share Q2 2026
$0.15 per share
Basic and diluted net loss per share for the three months ended June 30, 2026
Cash and cash equivalents
$211.6 million
Cash and cash equivalents as of June 30, 2026; company cites runway into 2H 2028
Equity offering gross proceeds
$125.0 million
Aggregate gross proceeds from May public offering of common stock and warrants
Additional proceeds on full warrant exercise
$194.4 million
Potential additional aggregate gross proceeds if all common stock warrants are exercised
Total stockholders’ equity
$105.3 million
Total stockholders’ equity as of June 30, 2026
LDL-C reduction in NHPs
≥90%
Mean LDL-C reduction with a single dose of EDIT-401 in non-human primates through ~6 months
Key Terms
Clinical Trial Notification (CTN), Heterozygous Familial Hypercholesterolemia (HeFH), restructuring and impairment charges, lipoprotein(a) (Lp(a)), +2 more
6 terms
Clinical Trial Notification (CTN) regulatory
"Editas is on track to submit a Clinical Trial Notification (CTN) in Australia"
A clinical trial notification (CTN) is a formal notice filed with regulators or ethics bodies before enrolling people in a human drug or device study; it summarizes the study plan, safety measures, informed consent process and who is legally responsible for the trial. For investors, a CTN is a key regulatory milestone that affects whether a trial can start, how quickly a product can move toward approval, and the project’s risk and timeline — like securing a permit before construction.
Heterozygous Familial Hypercholesterolemia (HeFH) medical
"Phase 1/2 clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH)"
restructuring and impairment charges financial
"Restructuring and impairment charges decreased by $27.4 million to a $1.3 million benefit"
Restructuring and impairment charges are accounting entries that reflect costs from reorganizing a business and from recognizing that assets are worth less than previously recorded. Think of restructuring as paying to rearrange or shrink your operations (like closing a shop or laying off staff), and impairment as writing down the value of an asset that no longer earns as much as expected (like admitting an old machine is obsolete). They matter to investors because they reduce reported profits, can signal management action or deeper problems, and affect future cash flows and valuation.
lipoprotein(a) (Lp(a)) medical
"mean reductions in LDL cholesterol (LDL-C), lipoprotein(a) (Lp(a)), and apolipoprotein B (ApoB)"
apolipoprotein B (ApoB) medical
"mean reductions in LDL-C, Lp(a), and apolipoprotein B (ApoB) with EDIT-401 in NHPs"
Cas12a patent estate technical
"Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate"
Earnings Snapshot
Net loss: $18.2 million · Guidance included
three months ended June 30, 2026
Net loss
$18.2 million
compared with $53.2 million for the three months ended June 30, 2025
Revenue
$11.9 million
compared with $3.6 million for the three months ended June 30, 2025
Net loss per share
$0.15 basic and diluted
compared with $0.63 basic and diluted for the three months ended June 30, 2025
Cash and cash equivalents
$211.6 million
compared with $146.6 million as of December 31, 2025
Guidance
The company expects existing cash and cash equivalents to fund operating expenses and capital expenditure requirements into the second half of 2028.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were Editas Medicine (EDIT) key financial results for Q2 2026?
Editas reported a Q2 2026 net loss of $18.2 million, or $0.15 per share, on collaboration and other R&D revenue of $11.9 million. A year earlier, net loss was $53.2 million, or $0.63 per share, on $3.6 million revenue.
What is Editas Medicine (EDIT) current cash position and runway?
As of June 30, 2026, Editas had $211.6 million in cash and cash equivalents, up from $146.6 million at December 31, 2025. The company expects this to fund operating and capital needs into the second half of 2028.
What progress did Editas Medicine (EDIT) report on its EDIT-401 program?
Editas said EDIT-401 is on track for a Clinical Trial Notification in Australia this month and a Phase 1/2 trial in HeFH. It expects a data update in Q1 2027 and topline dose-finding data in 2027, pending study progress.
What recent financing did Editas Medicine (EDIT) complete?
In May, Editas completed a public offering of common stock and warrants, raising aggregate gross proceeds of $125.0 million. If all warrants issued in the deal are exercised at their exercise price, Editas would receive about an additional $194.4 million in gross proceeds.
What board changes did Editas Medicine (EDIT) announce?
Editas disclosed that director Elliott Levy, M.D. resigned effective August 4, 2026, without any stated disagreement. On August 4, the board appointed Patrick Ellinor, M.D., Ph.D. as an independent class I director, effective August 6, 2026.
How did restructuring and impairment items affect Editas Medicine (EDIT) Q2 2026 results?
Restructuring and impairment contributed a $1.3 million benefit in Q2 2026, compared with $26.1 million in charges a year earlier. The change mainly reflects favorable adjustments to previously estimated contract costs related to discontinuation of the reni-cel program.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________________________________________
FORM 8-K
_________________________________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 3, 2026
_________________________________________________________________________________________
(Exact Name of Registrant as Specified in its Charter)
_________________________________________________________________________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
Registrant’s telephone number, including area code: (617 ) 401-9000
(Former Name or Former Address, if Changed Since Last Report)
__________________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2026, Editas Medicine, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended June 30, 2026 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 3, 2026, Elliott Levy, M.D., a member of the Board of Directors (the “Board”) of the Company who was serving as a class I director, resigned from the Board, effective August 4, 2026. The resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
On August 4, 2026, the Board, upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Patrick Ellinor, M.D., Ph.D. as an independent director, effective August 6, 2026. Dr. Ellinor has been designated as a class I director to serve in accordance with the Company’s By-Laws.
Dr. Ellinor currently serves as Executive Director of the Heart and Vascular Institute at Mass General Brigham, a role he has held since December 2024. He has also served as an Institute Member and Director of the Cardiovascular Disease Initiative of the Broad Institute of Harvard and MIT since October 2014, as a Professor of Medicine at Harvard Medical School since July 2003, and as the Telemachus and Irene Demoulas Family Foundation Endowed Chair in Cardiology at Massachusetts General Hospital since June 1998. Dr. Ellinor received a B.S. in Biology from the University of Cincinnati and both a Ph.D. in Physiology and an M.D. from Stanford University. He did his medical internship and residency at Brigham and Women’s Hospital in Boston and completed fellowship training in cardiology and cardiac electrophysiology at Massachusetts General Hospital.
In accordance with the Company’s director compensation policy, Dr. Ellinor will receive (i) annual cash compensation of $40,000 as a member of the Board and reimbursement for reasonable travel and other expenses incurred in connection with attending meetings of the Board and committees thereof and (ii) an option to purchase 103,400 shares of the Company’s common stock, with an exercise price equal to the closing price of the Company’s common stock on the Nasdaq Global Select Market on the date of appointment, which option will vest as to one-third of the shares of common stock underlying the option in three equal installments on each anniversary of the date of grant. Dr. Ellinor has entered into a standard form of indemnification agreement with the Company, in the form that is filed as Exhibit 10.28 to the Company’s Registration Statement on Form S-1 (File No. 333-208856), filed with the Securities and Exchange Commission on January 4, 2016.
There is no arrangement or understanding between Dr. Ellinor and any other person pursuant to which Dr. Ellinor was selected as a director. In addition, Dr. Ellinor is not a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press release issued by the Company on August 5, 2026* | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
*This exhibit shall be deemed to be furnished and not filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EDITAS MEDICINE, INC. | ||||||||
| Date: August 5, 2026 | By: | /s/ Amy Parison | ||||||
| Amy Parison | ||||||||
| Chief Financial Officer | ||||||||
Exhibit 99.1
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
EDIT-401 on track for CTN submission this month with data update in Q1 2027
Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, including LDL-C, Lp(a) and ApoB with EDIT-401 in non-human primates
Recent financing strengthens Company’s capital position, supporting continued advancement of EDIT-401 program, with cash runway into the second half of 2028
CAMBRIDGE, Mass., August 5, 2026 – Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the second quarter 2026 and provided business updates.
“During the second quarter, we continued preclinical work to support advancing EDIT-401 into a single ascending dose, open-label Phase 1/2 study,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. “We also presented new preclinical data demonstrating the ability of a single dose of EDIT-401 to achieve rapid and significant reductions in multiple atherogenic lipoproteins in non-human primates along with a promising preclinical safety profile, reinforcing EDIT-401’s potential as a best-in-class, one-time treatment for hyperlipidemia. In addition, with our recent equity financing, we are well capitalized to drive the clinical development of EDIT-401 through key value-creating milestones. We look forward to our continued progress and expect to provide a data update in the first quarter of 2027.”
EDIT-401
•Editas presented new EDIT-401 preclinical data at the 94th European Atherosclerosis Society (EAS) Congress, the 2026 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), and TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, including:
◦A single dose of EDIT-401 achieved ~90 percent or greater mean reductions in LDL cholesterol (LDL-C), lipoprotein(a) (Lp(a)), and apolipoprotein B (ApoB), with rapid and dose-dependent effect, in non-human primates (NHPs).
◦LDL-C mean reduction of ≥90% with a single dose of EDIT-401 in NHPs was durable through ~6 months.
◦No adverse clinical observations were observed in NHPs at a single dose of 1.5mg/kg.
•Editas is on track to submit a Clinical Trial Notification (CTN) in Australia this month and continues to progress towards initiating a Phase 1/2 clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH).
◦The Phase 1/2 study will evaluate the safety, tolerability, and efficacy of a single dose of EDIT-401. The trial is designed in two parts. Part 1 of the study is a single ascending dose, open-label trial design. Editas has selected four clinical trial sites across Australia and New Zealand.
◦The Company expects to report a data update in the first quarter of 2027.
◦Editas plans to complete enrollment in Part 1, the dose-finding portion of the Phase 1/2 trial of EDIT-401, with topline data results available in 2027.
Corporate & Business Development Updates
•In May, Editas completed a public offering of common stock and accompanying common stock warrants. The aggregate gross proceeds from the offering were $125.0 million, before deducting underwriting discounts and commissions and offering expenses. In addition, if all common stock warrants are exercised at their exercise price, the Company would receive additional gross proceeds from the offering of approximately $194.4 million before deducting underwriting discounts and commissions and offering expenses.
•Editas announced the appointment of Patrick T. Ellinor, M.D., Ph.D. to its Board of Directors. Dr. Ellinor is a recognized leader in cardiovascular medicine and human genetics and brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership to Editas.
Second Quarter 2026 Financial Results
Cash and cash equivalents as of June 30, 2026, were $211.6 million compared to $146.6 million as of December 31, 2025. The Company expects that the existing cash and cash equivalents will enable the Company to fund its operating expenses and capital expenditure requirements into the second half of 2028.
Second Quarter 2026
•For the three months ended June 30, 2026, net loss attributable to common stockholders was $18.2 million, or $0.15 per share, compared to net loss of $53.2 million, or $0.63 per share, for the same period in 2025.
•Collaboration and other research and development revenues increased to $11.9 million for the three months ended June 30, 2026, compared to $3.6 million for the same period in 2025. The increase was primarily attributable to the recognition of deferred revenue related to the expiration certain rights to opt-in to additional research programs under its collaboration with BMS.
•Research and development expenses increased by $4.0 million to $20.2 million for the three months ended June 30, 2026, compared to $16.2 million for the same period in 2025. The decrease is primarily related to increased external expenses for ongoing research and preclinical efforts for EDIT-401.
•General and administrative expenses decreased by $1.3 million to $11.6 million for the three months ended June 30, 2026 compared to $12.9 million for the same period in 2025. The decrease is primarily attributable to a reduction in employee-related expenses, as well as reduced professional services, in connection with the reduction in headcount (the “Reduction”) and discontinuation of the clinical development of the Company’s reni-cel program (the “Discontinuation”) initiated in December 2024 and ongoing throughout 2025.
•Restructuring and impairment charges decreased by $27.4 million to a $1.3 million benefit for the three months ended June 30, 2026 compared to $26.1 million for the same period in 2025. The decrease is primarily attributable to favorable adjustments to prior estimated costs for contracts associated with the Discontinuation upon finalization of contract costs.
About Heterozygous Familial Hypercholesterolemia (HeFH)
Heterozygous Familial Hypercholesterolemia (HeFH) is an inherited genetic disorder that leads to significantly elevated LDL‑cholesterol levels from an early age. Individuals with HeFH are at high risk of heart disease, heart attack, or stroke if the condition is not identified and treated early. An estimated 1.2 million people in the United States are living with HeFH, though many remain undiagnosed. Elevated LDL-C, also known as hyperlipidemia, is a highly prevalent disease affecting over 70 million patients in the United States alone. Substantial unmet need exists across multiple at-risk segments of patients with hyperlipidemia, including the HeFH population.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the initiation, timing, progress and results of the Company’s preclinical studies and planned clinical trials, including the Company’s expectation to complete enrolling the dose-finding portion of the planned Phase 1/2 clinical trial of EDIT-401 with topline data results available in 2027; the timing for the Company’s receipt and presentation of data from its preclinical and planned clinical studies, including providing a data update on EDIT-401 in the first quarter of 2027; the potential of, and expectations for, EDIT-401; the timing or likelihood of regulatory submissions and approvals, including submission of a CTN in Australia this month; and the Company’s expectations regarding its cash runway. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation, timing, progress, and results of preclinical studies and clinical trials; uncertainty regarding availability and timing of results from preclinical studies and clinical trials; uncertainties relating to planned regulatory submissions to initiate clinical trials, including that results of preclinical studies will warrant such submissions or that regulatory agencies may require additional preclinical studies, that regulatory submissions shall occur on the expected timelines and that regulatory authorities will provide clearance for trials to be initiated on the expected timelines or at all; and uncertainties as to whether the Company’s cash resources are sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements for the period anticipated. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
EDITAS MEDICINE, INC.
Consolidated Statement of Operations
(amounts in thousands, except share and per share data)
(Unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Collaboration and other research and development revenues | $ | 11,890 | $ | 3,578 | $ | 14,721 | $ | 8,236 | |||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Research and development | 20,180 | 16,181 | 37,780 | 42,774 | |||||||||||||||||||
| General and administrative | 11,603 | 12,859 | 21,837 | 26,234 | |||||||||||||||||||
| Restructuring and impairment charges | (1,339) | 26,082 | (1,339) | 66,935 | |||||||||||||||||||
| Total operating expenses | 30,444 | 55,122 | 58,278 | 135,943 | |||||||||||||||||||
| Operating loss | (18,554) | (51,544) | (43,557) | (127,707) | |||||||||||||||||||
| Other income (expense), net: | |||||||||||||||||||||||
| Interest expense related to sale of future revenues | (1,061) | (2,020) | (2,133) | (4,236) | |||||||||||||||||||
| Interest income, net | 1,368 | 2,087 | 2,574 | 4,803 | |||||||||||||||||||
| Other income (expense), net | 17 | (1,758) | (96) | (2,183) | |||||||||||||||||||
| Total other income (expense), net | 324 | (1,691) | 345 | (1,616) | |||||||||||||||||||
| Net loss | $ | (18,230) | $ | (53,235) | $ | (43,212) | $ | (129,323) | |||||||||||||||
| Net loss per share, basic and diluted | $ | (0.15) | $ | (0.63) | $ | (0.40) | $ | (1.54) | |||||||||||||||
| Weighted-average common shares outstanding, basic and diluted | 119,294,615 | 84,412,200 | 108,646,137 | 83,737,382 | |||||||||||||||||||
EDITAS MEDICINE, INC.
Selected Consolidated Balance Sheet Items
(amounts in thousands)
(Unaudited)
| June 30, | December 31, | ||||||||||
| 2026 | 2025 | ||||||||||
| Cash and cash equivalents | $ | 211,645 | $ | 146,645 | |||||||
| Working capital | 149,633 | 117,649 | |||||||||
| Total assets | 237,364 | 186,534 | |||||||||
| Deferred revenue, net of current portion | 4,000 | 44,509 | |||||||||
| Total stockholders' equity | 105,281 | 27,288 | |||||||||
###
Investor and Media Contacts:
ir@editasmed.com
media@editasmed.com